Nivolumab/Ipilimumab Combo Approved in Europe for Frontline RCC

January 15, 2019 – The European Commission has approved nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC), according to Bristol-Meyers Squibb (BMS), the developer of both immunotherapy agents. The approval is based on findings from the phase III CheckMate-214 trial, which demonstrated that the combination of nivolumab plus ipilimumab led to … (leggi tutto)